Longitudinal Assessment of Preterm Infants Treated with Erythropoiesis Stimulating Agents.
Curr Pediatr Rev
; 19(4): 417-424, 2023.
Article
en En
| MEDLINE
| ID: mdl-36537596
ABSTRACT
OBJECTIVE:
We previously reported improved neurodevelopment at 2 and 4 years among preterm infants treated with erythropoietin or darbepoetin, known as erythropoiesis-stimulating agents (ESAs). We now characterize longitudinal outcomes through 6 years.METHODS:
Children randomized to ESAs or placebo were evaluated at 6 years. Healthy-term children served as controls. Tests of cognition and executive function (EF) were performed.RESULTS:
Cognitive/EF scores remained similar between 4 and 6 years within each group (ESA 43 children; placebo 17 children; term 21 children). ESA recipients scored higher than placebo on Full-Scale IQ (94.2 ± 18.6 vs. 81.6 ± 16.7, p = 0.022), and Performance IQ (97.3 ± 16.2 vs. 81.7 ± 15.2, = 0.005). Aggregate EF trended better for the ESA group. Term controls scored better than placebo on all measures. ESA and term controls scored similarly on cognitive and EF tests.CONCLUSION:
ESA recipients had better outcomes than placebo recipients, and were similar to term children. ESAs may improve long-term cognition and executive function in preterm infants.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Hematínicos
Tipo de estudio:
Clinical_trials
Límite:
Child
/
Humans
/
Infant
/
Newborn
Idioma:
En
Revista:
Curr Pediatr Rev
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos